Amneal Pharmaceuticals Stock EBITDA
| 2DT Stock | EUR 7.30 0.25 3.31% |
Amneal Pharmaceuticals fundamentals help investors to digest information that contributes to Amneal Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Amneal Stock. The fundamental analysis module provides a way to measure Amneal Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Amneal Pharmaceuticals stock.
Amneal |
Amneal Pharmaceuticals Company EBITDA Analysis
Amneal Pharmaceuticals' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Amneal Pharmaceuticals EBITDA | 401.1 M |
Most of Amneal Pharmaceuticals' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Amneal Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
According to the company disclosure, Amneal Pharmaceuticals reported earnings before interest,tax, depreciation and amortization of 401.1 M. This is 54.29% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The ebitda for all Germany stocks is 89.71% higher than that of the company.
Amneal EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Amneal Pharmaceuticals' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Amneal Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Amneal Pharmaceuticals by comparing valuation metrics of similar companies.Amneal Pharmaceuticals is currently under evaluation in ebitda category among its peers.
Amneal Fundamentals
| Return On Equity | -0.88 | |||
| Return On Asset | 0.0257 | |||
| Profit Margin | (0.06) % | |||
| Operating Margin | 0.08 % | |||
| Current Valuation | 2.95 B | |||
| Shares Outstanding | 151.48 M | |||
| Shares Owned By Insiders | 10.80 % | |||
| Shares Owned By Institutions | 67.79 % | |||
| Price To Earning | 8.70 X | |||
| Price To Book | 1.17 X | |||
| Price To Sales | 0.29 X | |||
| Revenue | 2.09 B | |||
| Gross Profit | 783.95 M | |||
| EBITDA | 401.1 M | |||
| Net Income | 10.62 M | |||
| Cash And Equivalents | 452.1 M | |||
| Cash Per Share | 3.04 X | |||
| Total Debt | 2.72 B | |||
| Debt To Equity | 7.78 % | |||
| Current Ratio | 2.45 X | |||
| Book Value Per Share | 1.96 X | |||
| Cash Flow From Operations | 241.82 M | |||
| Earnings Per Share | (0.73) X | |||
| Target Price | 7.33 | |||
| Number Of Employees | 7 K | |||
| Beta | 1.37 | |||
| Market Capitalization | 712.21 M | |||
| Total Asset | 3.94 B | |||
| Net Asset | 3.94 B |
About Amneal Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Amneal Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Amneal Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Amneal Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Amneal Stock
Amneal Pharmaceuticals financial ratios help investors to determine whether Amneal Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Amneal with respect to the benefits of owning Amneal Pharmaceuticals security.